DUO-E: This phase III trial will assess the safety and effectiveness of a targeted cancer drug, given in combination with chemotherapy and followed by maintenance therapy, in patients with advanced or recurrent endometrial cancerA Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Summary

Eligible patients will be randomised into one of three Arms of the trial (Arm A, B or C). Depending on their allocation, patients will receive Platinum-based chemotherapy and durvalumab placebo followed by maintenance therapy, containing durvalumab placebo and olaparib placebo (tablets), durvalumab and olaparib placebo or durvalumab and olaparib. : Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets). Drug: durvalumab placebo : Olaparib tablets This Phase III study will assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.Target patient population: Adult female patients with histologically confirmed diagnosis of epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly diagnosed Stage IV, or recurrent endometrial cancer